Skip to main content
. 2018 Apr 27;36(18):1788–1797. doi: 10.1200/JCO.2017.77.6757

Fig 3.

Fig 3.

Prognostic impact of mutation clearance at day 30 complete remission marrow in patients with acute myeloid leukemia. Event-free survival (EFS) for patients who achieved complete remission according to three levels of residual somatic mutation. (A) MC2.5 (mutation clearance with residual variant allele frequency [VAF] < 2.5%). (B) MC1.0 (mutation clearance with residual VAF < 1%). (C) complete mutation clearance (CMC). (D-F) Overall survival (OS) according to (D) MC2.5, (E) MC1.0, and (F) CMC. (G-I) Cumulative incidence of relapse (CIR) according to (G) MC2.5, (H) MC1.0, and (I) CMC. Median follow-up was 28.5 months (95% CI, 24.0 to 35.2 months), 28.5 months (95% CI, 24.0 to 34.6 months), and 28.3 months (95% CI, 23.3 to 35.2 months) for those who achieved MC2.5, MC1.0, and CMC, respectively. P values were adjusted for multiple testing using the Bonferroni method considering nine test times.